6.Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med, 2015,Sep 27. 7.Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds i...
An abstract is unavailable.StockwellSerena
If yourbreast cancerhas a significant number of receptors for either estrogen or progesterone, it’s considered hormone-receptor positive. Tumors that are ER/PR-positive are much more likely to respond to hormone therapy than tumors that are ER/PR-negative. ...
High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors[J]. Cancer, 2015, 121(19):3422-3427. [4]Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update...
Small, hormone receptor-positive (HR+), HER2-negative (HER2-), lymph node-negative breast cancers are associated with relatively low rates of disease recurrence and have therefore been underrepresented in clinical trials assessing the effects of systemic
[1]‘FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer’,新闻发布。FDA。2023年1月27日发布。 [2] Bidard FC、Kaklamani VG、Neven P 等人。‘Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for est...
: This article aims to discuss elacestrant, an oral selective estrogen receptor downregulator approved by the Food and Drug Administration (FDA) in January 2023 for the treatment of hormone receptor positive (HR ) human epidermal growth factor receptor 2 negative (HER2) advanced breast cancer. ...
ER-positive, HER-2-negative operable breast cancer represents a mixed group of tumors where the identification of distinct clinical entities is the key achievement for proper management. On the one extreme, patients with ER-positive, HER-2-negative disease may have tumors with very low risks of...
1.Saji S, Taira N, Kitada M et al. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a rand...
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer (ER)-negative breast cancer specimens are predominantly of high grade, have frequent p53 mutations, and are broadly divided into HER2-positive and basal ... AE Teschendorff,A ...